CN118019728A - 作为可溶性环氧化物水解酶抑制剂的化合物 - Google Patents

作为可溶性环氧化物水解酶抑制剂的化合物 Download PDF

Info

Publication number
CN118019728A
CN118019728A CN202280037466.1A CN202280037466A CN118019728A CN 118019728 A CN118019728 A CN 118019728A CN 202280037466 A CN202280037466 A CN 202280037466A CN 118019728 A CN118019728 A CN 118019728A
Authority
CN
China
Prior art keywords
group
hexahydro
disease
chloro
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280037466.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·科多尼一世·吉斯伯特
C·G·格里安·费雷
M·帕拉斯·利比里亚
S·瓦兹克斯·克鲁兹
吴裕敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona
Original Assignee
Universitat de Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona filed Critical Universitat de Barcelona
Publication of CN118019728A publication Critical patent/CN118019728A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/76—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
    • C07C2603/78—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing seven-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202280037466.1A 2021-03-24 2022-03-14 作为可溶性环氧化物水解酶抑制剂的化合物 Pending CN118019728A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382237.2 2021-03-24
EP21382237.2A EP4063348A1 (en) 2021-03-24 2021-03-24 Compounds as soluble epoxide hydrolase inhibitors
PCT/EP2022/056557 WO2022200105A1 (en) 2021-03-24 2022-03-14 Compounds as soluble epoxide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
CN118019728A true CN118019728A (zh) 2024-05-10

Family

ID=75223297

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037466.1A Pending CN118019728A (zh) 2021-03-24 2022-03-14 作为可溶性环氧化物水解酶抑制剂的化合物

Country Status (5)

Country Link
US (3) US20240182406A1 (cg-RX-API-DMAC7.html)
EP (2) EP4063348A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512553A (cg-RX-API-DMAC7.html)
CN (1) CN118019728A (cg-RX-API-DMAC7.html)
WO (1) WO2022200105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain
CN117731650A (zh) * 2023-12-19 2024-03-22 重庆医科大学 一种防治高糖饮食所致肠损伤的方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2210799A1 (de) 1972-03-07 1973-09-20 Basf Ag 5,9:7,11-dimethano-8-hetero-11h-5,6. 7.8.9.10-hexahydro-benzo-cyclononene
DE2261637A1 (de) 1972-12-16 1974-06-20 Basf Ag 5,8 : 7.10-dimethano-5.6.7.8.9.10-hexa-hydro-benzo-cyclooctene und verfahren zu ihrer herstellung
AU1317000A (en) 1998-10-20 2000-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Method of treating immunological disorders mediated by t-lymphocytes
WO2003002555A1 (en) 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Methods of using soluble epoxide hydrolase inhibitors
EP1909796A4 (en) 2005-07-12 2009-11-11 Univ California USE OF EPOXY EICOSATRIC ACIDS AND INHIBITORS OF SOLUBLE EPOXY HYDROLASE FOR THE TREATMENT OF EYE DISEASES
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
JP2010521456A (ja) * 2007-03-13 2010-06-24 アレテ セラピューティクス, インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
WO2009086426A2 (en) * 2007-12-28 2009-07-09 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
WO2010025043A1 (en) * 2008-08-29 2010-03-04 Arete Therapeutics, Inc. Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases
US9034903B2 (en) 2012-02-01 2015-05-19 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
BR112016021641A2 (pt) 2014-03-27 2017-08-15 Eicosis Llc Potentes inibidores da epóxido hidrolase solúveis
US10813894B2 (en) 2015-02-20 2020-10-27 The Regents Of The University Of California Methods of inhibiting pain
CA2993882A1 (en) 2015-07-28 2017-02-02 Universitat De Barcelona Analogs of adamantylureas as soluble epoxide hydrolase inhibitors
US11123311B2 (en) 2016-01-05 2021-09-21 The Regents Of The University Of California Methods of treating mental disorders
EP3584236A1 (en) 2018-06-20 2019-12-25 Universitat de Barcelona Polycyclic compounds soluble epoxide hydrolase inhibitors
US12485107B2 (en) 2019-01-11 2025-12-02 Beth Israel Deaconess Medical Center, Inc. Methods for the prevention or treatment of cytokine storm

Also Published As

Publication number Publication date
JP2024512553A (ja) 2024-03-19
US20260193176A1 (en) 2026-07-09
EP4313947A1 (en) 2024-02-07
US12486222B2 (en) 2025-12-02
US20250115548A1 (en) 2025-04-10
WO2022200105A1 (en) 2022-09-29
EP4063348A1 (en) 2022-09-28
US20240182406A1 (en) 2024-06-06
WO2022200105A8 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US12486222B2 (en) Compounds as soluble epoxide hydrolase inhibitors
ES2304432T3 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenilaminas aciladas y su uso como productos farmaceuticos.
TWI461419B (zh) 作為γ-分泌酶調節劑之新穎經取代的吲唑及氮雜-吲唑衍生物類
CN1323307A (zh) 1h-咪唑并吡啶衍生物
WO2005040135A1 (ja) 抗ストレス薬およびその医薬用途
CZ20014126A3 (cs) Indolové deriváty jako inhibitory p38 kinasy
IL166494A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use for the manufacture of pharmaceuticals
JP2010508288A (ja) キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
CN104136436A (zh) 抗纤维化的化合物及其用途
KR20060027802A (ko) 3환계 화합물
IL166491A (en) Acylated arylcycloalkylamines and pharmaceutical compositions comprising them
CN106573907B (zh) 喹啉衍生物及其用于神经退化性疾病的用途
KR20160009052A (ko) Bace 억제제
JP6689848B2 (ja) トリペプチド化合物、その調製方法及びその用途
JP2007506692A6 (ja) 新規なピリジン誘導体
JP2007506692A (ja) 新規なピリジン誘導体
KR20160019893A (ko) 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-6,7-디하이드로[1,2,3]트리아졸로[1,5-a]피라진 유도체
Vaz et al. Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer’s disease
JP7442828B2 (ja) 可溶性エポキシド加水分解酵素阻害剤としての多環式化合物
KR20240155871A (ko) 소르틸린 의존성 질병의 치료를 위한 아미노산 기반 카바메이트 및/또는 요소
CN101790516A (zh) 作为hsp诱导剂的新的取代的哌啶酮
WO2004002483A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease
Rennhack et al. Synthesis of a potent photoreactive acidic γ-secretase modulator for target identification in cells
CN102119142B (zh) 作为烟碱α7调节剂的水杨酰胺衍生物
JP7834736B2 (ja) 環状アペリン受容体アゴニスト

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination